Semaglutide

New to peptides? Start with what are peptides? and how do peptides work?

Overview

Semaglutide mimics GLP-1 (glucagon-like peptide-1), a hormone your gut releases after eating that tells the body to release insulin, feel full, and stop eating. It stands apart from most compounds on this site because it has completed large, rigorous, randomized human trials and is an approved prescription medicine.

It is sold under three brand names for two purposes: Ozempic (weekly injection) and Rybelsus (daily tablet) for type 2 diabetes, and Wegovy (weekly injection, higher dose) for chronic weight management. The active molecule is the same; the dose and indication differ.

How it works

Semaglutide engages the GLP-1 receptor across several systems:

• Appetite & satiety. It acts on appetite centers in the brain to reduce hunger and food intake — the main driver of weight loss.
• Slowed gastric emptying. Food stays in the stomach longer, increasing fullness after meals.
• Glucose-dependent insulin secretion. It boosts insulin and suppresses glucagon only when blood sugar is elevated, which lowers glucose with a low risk of hypoglycemia on its own.^[1]

Clinical evidence

Semaglutide's evidence base is unusually strong for this field:

• STEP program (weight). In adults with overweight or obesity, weekly semaglutide produced mean weight loss far exceeding placebo over 68 weeks.^[1]
• SUSTAIN program (diabetes). Demonstrated significant improvements in HbA1c (blood-sugar control).
• SELECT trial (cardiovascular). In people with overweight/obesity and established cardiovascular disease but without diabetes, semaglutide reduced major adverse cardiovascular events versus placebo — a landmark result extending benefit beyond weight and glucose.^[2]

Dosing & side effects

Semaglutide is prescribed with gradual dose escalation over weeks to limit side effects. The most common are gastrointestinal: nausea, vomiting, diarrhea, and constipation, which often ease over time. It carries a boxed warning regarding thyroid C-cell tumors (based on rodent findings) and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. Pancreatitis and gallbladder issues are less common considerations. It must be used under medical supervision.

Legal status

FDA-approved and prescription-only. Because of high demand, "compounded" and "research" semaglutide sold outside the regulated pharmacy supply chain has proliferated; these carry real quality, dosing, and safety concerns and are not the same as the approved product.

How good is the evidence, really?

Semaglutide is the rare case on this site where the honest answer is "unusually good", so it is worth being specific about why — and where the limits still are.

What makes it strong

• Randomised, placebo-controlled, and large. The STEP programme (weight management) and SUSTAIN programme (type 2 diabetes) enrolled thousands of participants across multiple trials, with pre-registered endpoints and independent review.
• Hard outcomes, not just surrogates. Most drugs in this category are judged on weight or blood sugar — numbers that stand in for health. The SELECT trial went further and measured cardiovascular events in people with overweight or obesity and established cardiovascular disease. Measuring events rather than markers is a materially higher bar.
• Regulatory scrutiny. The data were reviewed by the FDA and other agencies, which means an outside party with subpoena power examined the raw results rather than the published summary.
• Scale of real-world use. Millions of people have now taken it, which surfaces uncommon adverse effects that trials of a few thousand cannot.

Where the limits are

Durability. Weight regain after stopping is well documented. Trials show the effect depends on continued treatment, which reframes it as an ongoing therapy rather than a course of treatment — with cost and access implications that outlast the prescription.

Body composition. Rapid weight loss of this magnitude includes lean mass as well as fat, and how much matters over years is an active question rather than a settled one.

Trial populations versus real patients. Participants are screened, supported and monitored. Adherence and results in ordinary practice are consistently less impressive than in trials — true of nearly every drug, and worth remembering when comparing a headline percentage to your own expectations.

Approved semaglutide versus compounded semaglutide

A large share of the semaglutide people actually encounter is not the approved product, and the distinction is the single most consequential thing to understand about buying it.

Approved semaglutide — Ozempic, Wegovy, Rybelsus — is manufactured to pharmaceutical standards, tested batch by batch for identity and purity, and supported by the trial data described above. Everything on this page describes that product.

Compounded semaglutide is prepared by a compounding pharmacy rather than manufactured as an approved product. Compounding is a legitimate and long-standing part of medicine, but a compounded version is not an FDA-approved product: it has not been reviewed for safety, effectiveness or manufacturing quality in the way the branded drug has. Regulators have also warned about salt forms of semaglutide — such as semaglutide sodium or acetate — which are different substances from the approved base and have not been shown to be safe or effective.

Research-chemical semaglutide, sold online "for research use only", is a third category again: unapproved, unregulated, and of unverified identity and purity.

These are not shades of the same thing. The trial results that make semaglutide impressive attach to a specific, quality-controlled molecule — not to anything bearing the name. See are peptides legal? for how compounding rules have shifted.

Semaglutide vs Tirzepatide vs Liraglutide

The three best-known incretin-based weight/diabetes peptides differ in mechanism, dosing, and typical weight loss.

Frequently asked questions

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. Peer-reviewed study
2. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023. Peer-reviewed study
3. Chao AM, Tronieri JS, Amaro A, et al. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 2023. Peer-reviewed study
4. Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol (Lausanne). 2021. Peer-reviewed study
5. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021. Peer-reviewed study
6. Tan HC, Dampil OA, Marquez MM. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis. J ASEAN Fed Endocr Soc. 2022. Peer-reviewed study

Semaglutide in reference databases: Wikipedia · Wikidata · DrugBank · PubChem